Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy

被引:145
|
作者
Gao, Zhan-Shan [1 ]
Zhang, Chuan-Jie [2 ]
Xia, Nan [1 ]
Tian, He [3 ]
Li, Dao-Yong [2 ]
Lin, Jia-Quan [2 ]
Mei, Xi-Fan [2 ]
Wu, Chao [1 ]
机构
[1] Jinzhou Med Univ, Pharm Sch, Jinzhou, Peoples R China
[2] Jinzhou Med Univ, Dept Orthoped, Affifiliated Hosp 1, Jinzhou, Peoples R China
[3] Jinzhou Med Univ, Dept Histol & Embryol, Jinzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Exosomes; Berberine; Spinal cord injury; Macrophages/microglia; Inflammatory; MICROGLIA; RECOVERY; DAMAGE;
D O I
10.1016/j.actbio.2021.03.018
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Spinal cord injury (SCI) causes immune activation of resident macrophages/microglia. Activated macrophages/microglia have two different phenotypes, the pro-inflammatory classically activated (M1) phenotype and the anti-inflammatory alternatively activated (M2) phenotype. M1 phenotype macrophages/microglia are the key factor in inflammation. The treatment of SCI remains a huge challenge due to the nontargeting and inefficiency of anti-inflammatory drugs through the blood-brain barrier (BBB). The purpose of this experiment was to design M2-type primary peritoneal macrophages exosomes (Exos) as a drug carrier for berberine (Ber), which can be efficiently targeted to deliver drugs to the injured spinal cord due to the natural advantage of Exos across the BBB. The Exos with particle size of 125 +/- 12 nm were loaded with by an ultrasonic method and the drug loading reached 17.13 +/- 1.64%. The Ber release experiment showed that the loaded sample (Exos-Ber) exhibited sustained release effect, and the cumulative release amount reached 71.44 +/- 2.86% within 48 h. In vitro and in vivo experiments confirmed that the Exos-Ber could decrease the M1 protein marker iNOS, elevate the M2 protein marker CD206 and reduce inflammatory and apoptotic cytokines (TNF-alpha, IL-1 beta, IL-6, Caspase 9, Caspase 8), which showed that Exos-Ber had a good anti-inflammatory and anti-apoptotic effect by inducing macrophages/microglia from the M1 phenotype to M2 phenotype polarization. Moreover, the motor function of SCI mice was significantly improved after Exos-Ber treatment, indicating that Exos-Ber is a potential agent for SCI therapy. Statement of significance Efficient targeting strategy for drug delivery. In addition to good biocompatibility and stealth ability, M2 macrophage-derived Exosomes present natural inflammatory targeting ability. The inflammatory microenvironment after spinal cord injury provides motivation for the targeting of exosomes. Natural drug carrier with higher safety. With the rapid development of nanomaterials, drug carriers have become more selective. However, due to the special microenvironment after central nervous system damage, some non-degradable inorganic materials will increase the pressure of self-healing and even secondary damage to neurons, which has been solved by the emergence of exosomes. Some previous studies used tumor cell line exosomes as drug carriers, but the carcinogenic factors carried by themselves have extremely high hidden dangers, and endogenous macrophage exosomes have absolute advantages over their safety. (C) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:211 / 223
页数:13
相关论文
共 50 条
  • [1] Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy (vol 126, pg 211, 2021)
    Gao, Zhan-Shan
    Zhang, Chuan-Jie
    Xia, Nan
    Tian, He
    Li, Dao-Yong
    Lin, Jia-Quan
    Mei, Xi-Fan
    Wu, Chao
    ACTA BIOMATERIALIA, 2022, 140 : 745 - 746
  • [2] M2 macrophage-derived exosomes for bone regeneration: A systematic review
    Daneshvar, Alireza
    Nemati, Parisa
    Azadi, Ali
    Amid, Reza
    Kadkhodazadeh, Mahdi
    ARCHIVES OF ORAL BIOLOGY, 2024, 166
  • [3] M2 Macrophage-Derived Exosomes Inhibiting Neutrophil Extracellular Traps for Ischemic Stroke Therapy
    Wang, Zhenhua
    Qing, Hongrui
    Li, Ran
    Li, Xue
    Guo, Xing
    Zhou, Shaobing
    ADVANCED FUNCTIONAL MATERIALS, 2024, 34 (42)
  • [4] Sodium alginate and naloxone loaded macrophage-derived nanovesicles for the treatment of spinal cord injury
    Liu, Xiaoyao
    Jiang, Xue
    Yu, Qi
    Shen, Wenwen
    Tian, He
    Mei, Xifan
    Wu, Chao
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 17 (01) : 87 - 101
  • [5] Sodium alginate and naloxone loaded macrophage-derived nanovesicles for the treatment of spinal cord injury
    Xiaoyao Liu
    Xue Jiang
    Qi Yu
    Wenwen Shen
    He Tian
    Xifan Mei
    Chao Wu
    AsianJournalofPharmaceuticalSciences, 2022, 17 (01) : 87 - 101
  • [6] Berberine-loaded MSC-derived sEVs encapsulated in injectable GelMA hydrogel for spinal cord injury repair
    Wang, Heng
    Tang, Qin
    Lu, Yang
    Chen, Cheng
    Zhao, Yu-lin
    Xu, Tao
    Yang, Chang-wei
    Chen, Xiao-qing
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 643
  • [7] M2 MACROPHAGE-DERIVED EXOSOMES LOADED WITH SIRIPK3 ATTENUATE CONA-INDUCED IMMUNE HEPATITIS
    Zhang, Lu
    Liu, Man
    Chen, Liwei
    Zhang, Jie
    Zhou, Lu
    Wang, Bangmao
    Zhao, Jingwen
    GASTROENTEROLOGY, 2022, 162 (07) : S1227 - S1227
  • [8] M2 macrophage-derived exosomes promote diabetic fracture healing by acting as an immunomodulator
    Wang, Yili
    Lin, Qiushui
    Zhang, Hao
    Wang, Sicheng
    Cui, Jin
    Hu, Yan
    Liu, Jinlong
    Li, Mengmeng
    Zhang, Kun
    Zhou, Fengjin
    Jing, Yingying
    Geng, Zhen
    Su, Jiacan
    BIOACTIVE MATERIALS, 2023, 28 : 273 - 283
  • [9] M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer
    Lan, Jingqin
    Sun, Li
    Xu, Feng
    Liu, Lu
    Hu, Fuqing
    Song, Da
    Hou, Zhenlin
    Wu, Wei
    Luo, Xuelai
    Wang, Jing
    Yuan, Xianglin
    Hu, Junbo
    Wang, Guihua
    CANCER RESEARCH, 2019, 79 (01) : 146 - 158
  • [10] Minocycline-Loaded BMSC Exosomes Modulate M1/M2 Macrophage Polarization and Reduce Inflammation after Spinal Cord Injury
    Zhang, Kaihua
    Zhang, Chuanjie
    Feng, Huicong
    Mei, Xifan
    Zhao, Haosen
    ACS APPLIED NANO MATERIALS, 2024, 7 (13) : 15848 - 15863